Table 3. Poor prognostic factors of HCC after curative therapy.
| Variable | Case No. | Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | p | Hazard ratio (95% CI) | p | ||
| Age >65/≤65 years | 215/171 | 1.297(0.909–1.850) | 0.151 | ||
| Sex male/female | 280/106 | 1.116(0.752–1.658) | 0.585 | ||
| HBsAg positive/negative | 207/179 | 0.905(0.641–1.277) | 0.569 | ||
| Anti-HCV positive/negative | 134/252 | 0.979(0.683–1.403) | 0.908 | ||
| Albumin ≤4/>4 g/dL | 258/126 | 1.698(1.134–2.544) | 0.010 | ||
| Bilirubin >1.6/≤1.6 mg/dL | 50/336 | 1.755(1.126–2.735) | 0.013 | ||
| ALT > 40/≤40 U/L | 210/176 | 1.249(0.881–1.771) | 0.211 | ||
| AST > 45/≤45 U/L | 210/175 | 1.740(1.218–2.485) | 0.002 | ||
| Platelet ≤105/>105/mm3 | 125/261 | 1.990(1.403–2.823) | <0.001 | 1.909(1.303–2.797) | 0.001 |
| PT INR > 1.1/≤1.1 | 159/227 | 1.437(1.012–2.041) | 0.043 | ||
| Ascites (yes/no) | 63/323 | 1.938(1.305–2.877) | 0.001 | ||
| AFP > 20/≤20 ng/ml | 209/177 | 2.096(1.456–3.016) | <0.001 | 1.674(1.144–2.450) | 0.008 |
| Multiple tumor (yes/no) | 94/292 | 1.398(0.960–2.034) | 0.080 | ||
| Tumor size >3/≤3 cm | 166/220 | 1.532(1.086–2.161) | 0.015 | 1.844(1.249–2.723) | 0.002 |
| Vascular invasion (yes/no) | 21/365 | 3.659(2.009–6.665) | <0.001 | 3.312(1.797–6.103) | <0.001 |
| EGV (yes/no) | 143/243 | 1.597(1.129–2.257) | 0.008 | 1.629(1.117–2.376) | 0.011 |
Abbreviations: CI: confidence interval; HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; MELD: model for end-stage liver disease; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Alk-P: alkaline phosphate; PT INR: prothrombin time international normalized ratio; AFP: alpha-fetoprotein; EGV: esophagogastric varices.